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Background: Some reports suggest that patients with synchronous multiple foci of nonsmall-cell lung cancers
(NSCLC) distributed in multiple lobes have a poor prognosis, even when there is no extrathoracic metastasis. The vast
majority of such patients do not receive surgical treatment. For those who undergo surgery, prognostic factors are
unclear.
Patients and methods: We systematically reviewed the literature on surgery for synchronous NSCLC in multiple
lobes published between 1990 and 2011. Individual patient data were used to obtain adjusted hazard ratios (HRs) in
each dataset and pooled analyses were carried out.
Results: Six studies contributed 467 eligible patients for analysis. The median overall survival was 52.0 months [95%
confidence interval 45.6–63.7]. Male gender and advanced age were associated with a decreased survival: HRs 1.64
(1.22, 2.22) and 1.40 (1.20, 1.80) per 20-year increment, respectively. Patients with cancers distributed in one lung had
a higher mortality risk than those with bilateral disease: HRs 1.45 (1.06, 2.00). N1 or N2 had a decreased survival
compared with N0: HRs 1.68 (1.12, 2.51) and 1.94 (1.33, 2.82), respectively. There was a trend toward increased
mortality among patients with different histology: HRs 1.29 (0.96, 1.75).
Conclusion: Advanced age, male gender, nodal involvement, and unilateral tumor location were poor prognostic
factors.
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introduction
Surgery alone is a potentially curative treatment of early-stage,
nonsmall-cell lung cancer (NSCLC). However, as the stage of
NSCLC advances, the risk of metastasis increases, and the
efficacy of surgery, as a single modality, decreases. Determining
appropriate treatment of patients with isolated NSCLC is
generally straightforward. Nevertheless, when there are multiple
cancers in two or more lobes, this can be problematic. In the
absence of extrathoracic metastasis, these cancers may develop
from independent primaries or they may represent metastatic
foci. In the former scenario, surgery may be helpful; however, in
the latter scenario, surgery may not adequately address the
underlying systemic disease. Available data indicate that this
problem is not common. For example, data from 6596 patients
with ‘metastatic’ NSCLC submitted to the American Joint
Commission for Cancer Staging in 1990–2000 for M1
description indicated that 1106 patients (17%) had metastatic
disease solely on the basis of unilateral multiple lobe cancers and
369 (6%) on the basis of bilateral cancers [1]. Regardless of their
biological development, these cancers seem to portend a poor
prognosis overall. Several early studies have reported no long-
term survivors after surgery [2–6]. As a result, the vast majority
of such patients do not receive curative surgical treatment [7].
Nevertheless, attempts have been made to identify multiple
independent primary cancers as a target for surgical
intervention, on the premise that surgery is a curative
*Correspondence to: Dr T. Tanvetyanon, Department of Thoracic Oncology, H. Lee
Moffitt Cancer Center, University of South Florida, FOB-1, 12902 Magnolia Drive,
Tampa, FL 33612, USA. Tel: +1-813-745-3050; Fax: +1-813-745-3027; E-mail
tanvett@moffitt.org
Annals of Oncology reviews
© The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com.
Downloaded from https://academic.oup.com/annonc/article-abstract/24/4/889/257689
by Azienda Ospedaliera Careggi user
on 01 February 2018
treatment of early-stage cancers. In 1975, Martini and
Melamed introduced the first of such criteria [8]. Other
authors have since built upon this [9–11], though a few
common rules can be summarized. The first relies on
temporality: cancers with lag time >2–4 years are considered
independent primaries. Unfortunately, this is not helpful for
patients with synchronous cancers. The second rule relies on
histological similarity: cancers with similar histology are
metastatic, if there is carcinoma in lymphatics common to
both (i.e. mediastinal (N2) lymph node involvement).
However, this rule requires the precise knowledge about all
histological features of the cancers including the presence of
N2 involvement, making it impractical for use when surgery
has not taken place. Besides, the rule is not informative for
patients with N1 disease. In addition to these rules, the current
AJCC staging relies on location [1]: cancers with bilateral
location are metastatic. However, long-term survivors have
been reported after surgical resection among patients with
bilateral cancers [12, 13].
As there appears to be a room for improvement in the
prognostication of patients with synchronous multiple lung
cancers, in this article we systematically review the literature
specific to this patient population for their survival following
surgery. As available observational studies may have
inadequate statistical power or adjustment for the differences in
baseline characteristics, we perform a pooled analysis, using
individual patient data adjusting for multiple covariates
simultaneously, to identify the independent prognostic factors
for survival after surgery.
methods
search strategy
An institutional Scientific Review Committee has determined this study as
nonhuman subject research and exempted it from Institutional Review
Board. Electronic searches were carried out in Medline, PubMed, and Web
of Sciences databases from January 1990 to October 2011 with a restriction
to publications in English. To achieve the maximum sensitivity of the
search strategy and identify all publications relevant to surgical resection of
multiple lung cancers, we used appropriate free text and thesaurus terms
including ‘multiple’ or ‘second’ and the medical subject headings of ‘lung
neoplasm’, ‘surgical procedures, operative’, and ‘general surgery’. The
reference list of all retrieved articles was reviewed for further identification
of potentially relevant publications. In addition, abstracts from the
American Society of Clinical Oncology and European Society of Medical
Oncology were also searched for potential studies.
study selection
Eligible patients were those with multiple synchronous NSCLC located in
multiple lobes resected with curative intent. Patients who had satellite
nodules or cancers located in one lobe were included for analysis, providing
that they also had cancers located in multiple lobes. Synchronous cancers
were defined as those discovered within a 24-month time period, including
those found intraoperatively. To reduce reporting bias, studies reporting on
the survival outcome of at least 10 eligible patients were included. Excluded
studies were those solely reporting patients who had resections for benign
nodules, only one of the multiple cancers were resected, distant metastatic
disease, multiple cancers in only one lobe, or metachronous cancers.
Reports focusing on bronchioloalveolar carcinomas (BAC) in all lesions or
carcinoid tumors were also excluded. Corresponding authors of eligible
studies were contacted to obtain individual patient database for analysis.
data management and quality assessment
Databases were as supplied by collaborators. In two databases, time
variables were available in month to maintain patient confidentiality. Two
investigators (one clinical, T.T., and one nonclinical, W.J.F.) reviewed each
included article. Data retrieved from each report included publication
details, patient characteristics, and outcome measures. The data extracted
were entered into the Cochrane Collaboration software. Histological
difference was based on major histological type (i.e. adenocarcinoma versus
squamous cell carcinoma). Patients with cancers both in ipsilateral multiple
lobes and contralateral lung were analyzed together with the group of
patients who had solely bilateral cancers without ipsilateral involvement of
multiple lobes. Staging information was pathological. The quality of study
reporting was assessed based on the selected key elements, which may
affect the results and interpretations of our review [14]. Reporting was
conformed to the PRISMA statement [15].
statistical analysis
The main outcome was overall survival, defined as an interval between the
first resection and the date of death or last follow-up for censored cases. To
account for a possible heterogeneity among studies, a pooled analysis using
the technique of meta-analysis to pool effect sizes was conducted [16]. The
summary measure was a hazard ratio (HR). To calculate the adjusted HR
in each study, multivariable Cox proportional hazard models were fitted for
each study incorporating age, gender, tumor side, histological similarity,
nodal stage, and having pneumonectomy. The log-rank observed and
expected number of events and associated variances were calculated from
adjusted HR in each study [17]. The overall pooled HR and their 95%
confidence intervals (CI) were then calculated using a fixed effects model.
Chi-square heterogeneity tests were carried out. We calculated I2 statistics
expressing the proportion of variability in the results attributable to
heterogeneity rather than sampling error, with I2 statistic <25% indicating
low heterogeneity, 25%–50% moderate heterogeneity and >50% high
heterogeneity [18]. When moderate heterogeneity was observed, random
effects model was used to pool HR [19]. All P values were considered
significant at the level <0.05. All analyses were carried out using SAS
version 9.3 (Cary, NC) and Comprehensive Meta-Analysis from Statistical
Solutions (Saugus, MA).
results
study and patient characteristics
A total of 2805 titles were identified through electronic
database searches and screening of reference lists (Figure 1).
After excluding irrelevant reports, 114 publications were
retrieved for detailed evaluation. There were no duplicate
studies. Of these, 10 studies were eligible and individual patient
data were made available from six studies. All studies were
retrospective, published during 2008–2011, including patients
receiving surgery during 1983–2009. Two of these studies also
included patients with metachronous cancers or cancers
located in one lobe and data from only 467 eligible patients
were included for analysis from a total of 661 patients
originally reported (Table 1).
Overall, the patient median age was 69 years (range 42–86
years) and 54% were male. Tumor characteristics showed N0
325 patients (70%), N1 67 (14%), and N2 75 (16%); unilateral
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tumors 240 patients (51%) and bilateral tumors 227 patients
(49%); similar histology 314 patients (67%) and different
histology 153 (33%). Treatment characteristics showed
pneumonectomy was carried out in 57 patients (12%). The
duration between the first and the final operation was >6
months in 55 patients (12%).
Figure 1. Flow chart of study selection.
Table 1. Characteristics of analyzed patients
First authors, publication
year (reference)
Riquet, 2008 [25] Voltolini, 2010 [22] Finley, 2010 [11] Tanvetyanon, 2010 [21] Fabian, 2011 [23] Kocaturk, 2011 [24]
Treatment year 1983–2005 1990–2007 1995–2006 1997–2008 1996–2009 2001–2008
Total number of patients 234a 43 175b 116 67 26
Total number of analyzed
patients
61 43 154 116 67 26
Male gender (%) 77 95 41 41 45 100
Age (%)
<55 16 9 8 5 6 35
55–65 46 28 24 20 19 38
65–75 28 54 47 49 42 23
>75 10 9 21 26 33 4
N stage (%)
N0 49 58 71 81 82 42
N1 10 19 15 7 10 58
N2 41 23 14 12 7 0
Tumor location (%)
Unilateral 84 35 52 49 34 54
Bilateral 16 65 48 51 66 46
Histology (%)
Similar 56 63 82 68 56 65
Different 44 37 18 32 54 35
Pneumonectomy 43 14 3 9 0 42
aOriginal report included 234 patients; data from 61 patients with synchronous cancers in multiple lobes presented in this table.
bOriginal report included 175 patients; data from 154 patients with cancers in multiple lobes presented in this table.
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quality of study reporting
Although no uniform agreement exists regarding the
instrument to assess the quality of study reporting, for an
observational study, it is generally recommended that relevant
details regarding participant selection and measurement of key
variables be assessed [14, 20]. We considered specific reporting
issues, which, if inadequate, could compromise the results of
our analysis. For our review purpose, we evaluated the studies
for an explicit reporting of (1) method to exclude patients with
an extrathoracic disease, (2) whether BAC was distinguished
from an invasive adenocarcinoma, (3) method of mediastinal
staging, (4) number of sublobar resections, (5) number of
patients with positive surgical margins or receiving adjuvant
therapy, and (6) method of follow-up or last follow-up date.
Overall, we found the quality of reporting in these studies to
be acceptable for data synthesis. All but one study explicitly
specified the methodology used to exclude patients with
extrathoracic metastasis. The use of preoperative Positron
Emission Tomography scan in selected patients was described
in five of six studies. However, most did not specify the
number of patients who underwent the scan. The majority of
patients with N2 disease were those with microscopic N2. Of
six studies, three indicated an exclusion from surgery for
patients with known N2 [11], bulky or multistation N2 [21],
>1 cm N2 [22]. One study excluded N2 patients from analysis
if the histology was similar [23]. One study excluded all N2
patients from analysis [24] and finally, the other study did not
specify N2 policy [25].
surgery and outcomes
Surgical characteristics and outcomes are summarized
(Table 2). These results are not exclusively from eligible
patients. Sublobar resections occurred frequently, ranging from
16% to 78% of patients. The reported postoperative mortality
rate ranged from 1.2% to 7.6% of patients. At the time of
reporting, 248 patients have died. The median overall survival
was 52.0 months (95% CI 45.6–63.7). The likelihood of death
within 30 days from surgery was 1.9%. Most patients had two
cancers; however, 35 patients (7%) had three cancers, 12
patients (3%) had four cancers, and five (1%) patients had
greater than four cancer foci.
prognostic factors for survival
We pooled the adjusted HRs obtained from each study, taking
into account gender, age, pneumonectomy, nodal stage,
histological similarity, and tumor location. Gender, age, nodal
stage, and tumor location were significant predictors of
survival. Female gender was associated with a decreased
mortality: HR 0.61 (95% CI 0.45–0.82), P = 0.001. Increased
age (per year) was associated with increased mortality: HR
1.02 (95% CI 1.01–1.04), P = 0.006. N1 or N2 stage, when
compared with N0, was associated with increased mortality:
HR 1.68 (95% CI 1.12–2.51), P = 0.01, and HR 1.94 (95% CI
1.33–2.82), P = 0.005, respectively. Bilateral tumor location was
associated with a decreased mortality: HR 0.69 (95% CI 0.50–
0.94), P = 0.02. There was a trend toward increased mortality
risk among patients with different histology: HR 1.29 (95% CI
0.96–1.75), P = 0.09. Moderate heterogeneity was observed on
gender and tumor location analyses. However, when re-
examined using a random effects model, female gender and
bilateral tumor location remained significant favorable
predictors of survival: HR 0.63 (95% CI 0.43–0.93), P = 0.02
and HR 0.62 (95% CI 0.38–0.99), P = 0.048 respectively. We
carried out a subgroup analysis based on data obtained from
patients who completed all their surgical operations within a 6-
month period. In this subgroup, there were 412 patients with a
Table 2. Characteristics of surgery and adjuvant treatments
First authors, publication
year (reference)
Riquet,
2008 [25]
Voltolini,
2010 [22]
Finley,
2010 [11]
Tanvetyanon,
2010 [21]
Fabian,
2011 [23]
Kocaturk,
2011 [24]
Total number of patients originally
reported
118a 43 175 116 67 26
Patients with ≥2 surgical
procedures
NR 65.1 40.7 58.6 80.6 46.2
Patients with ≥3 cancers (%) NR 14.0 28.6 7.8 4.5 7.7
Patients with at least one sublobar
resection (%)
16.1 65.1 54.3 78.4 62.7 38.5
Patients with multistaged
resections (%)
NR 65.1 41.7 58.6 67.1 46.1
Pneumonectomy (%) 34.7 13.9 2.9 8.6 1.5 38.5
Adjuvant/neoadjuvant therapy (%)
Chemotherapy NR 34.9 9.7 20.7 25.0 NR
Radiotherapy NR 10.0 4.6 14.7 3.0 NR
Any of the above 41.5 39.5 14.3 31.0 26.9 NR
Operative mortality rate (%) 5.1 6.9 1.2 4.3 2.9 7.6
Most frequent complications (%) NR Air leak (13.9%) NR Arrhythmia (8.6%),
infection (8.6%)
NR NR
NR, data not reported.
aOriginal study reported on 234 patients; data specific to 118 patients with multiple synchronous cancers presented in this table.
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median survival of 50.7 months (95% CI 64.4–80.0). We found
similar trends as observed in the whole group.
To illustrate the impact of these prognostic factors, we
created a Kaplan–Meier estimate of survival using a pooled
dataset from six studies. Patients were categorized into two
groups based on the presence of risk factors (gender, age,
nodal stage, and tumor location). For the age variable, we
empirically chose to use a cutoff at <70 versus ≥70 years
because the median age of the patients was 69 years. We found
that patients with no risk factor (N = 43) had a considerably
better survival than those with ≥1 adverse risk factor
(N = 424). The estimated 5-year survival rate was 82% (95% CI
70–96) among those with risk factors absent versus 43% (95%
CI 38–48) among those with risk factor(s) present (Figure 2).
discussion
In this study of synchronous lung cancers located in multiple
lobes, we found that male gender, advanced age, higher nodal
stages, and unilateral tumor location were adverse predictors of
survival after surgical resection. The strongest predictor was N2
(1.94 times higher than N0), followed by N1 (1.68 times higher
than N0), male gender (1.64 times higher than female),
unilateral tumor location (1.45 times higher than bilateral),
and age (∼1.40 times higher every 20-year increase because
each year adds 0.02 to the number), respectively.
Pneumonectomy, previously suggested by some authors as a
poor prognostic factor [12], was not found to affect survival.
Histological similarity, also suggested by some as a poor
prognostic factor [26], was not associated with poor survival.
In fact, there was a trend toward improved survival among
patients with similar histology.
In line with our observations, other studies, albeit with
somewhat different patient inclusion criteria, have previously
suggested a more favorable survival among patients with
bilateral cancers [12] and similar histology [27, 28] than their
counterparts. It is hypothetically possible that patients with
bilateral cancers or similar histology may include a significant
number of those with mixed adenocarcinoma with BAC
component. BAC, now known as adenocarcinoma in situ in
the latest WHO classification, tends to occur among young
women, may manifest multifocally or bilaterally, and can run
an indolent course [29, 30]. The higher the proportion of BAC
component exists in a given invasive adenocarcinoma, the
better the prognosis [31]. Although we excluded studies
focusing on pure BAC, we were unable to exclude studies
containing invasive adenocarcinoma with BAC feature.
Alternatively, the survival among patients with bilateral disease
may be favorable simply because such patients are more likely
to be those with true multiple primary cancers. Given the
distance between cancers, patients with bilateral cancers, which
truly arise from hematogenous spread will likely have obvious
extrathoracic metastases, rendering them not a surgical
candidate. Finally, it is also possible that patients with bilateral
cancers are generally more select group than those with
unilateral cancers, given the prevailing notion that bilateral
cancers confer a poorer prognosis than unilateral cancers.
The observed favorable prognosis among patients with
bilateral cancers seems to be somewhat discordant with the
seventh edition of AJCC staging system, which classifies
bilateral cancers as stage IV (M1a), but classifies unilateral
cancers in multiple lobes as stage III (T4) [1]. This discordance
probably stems from the fact that that only 2% of patients with
bilateral cancers who formed the basis of AJCC staging
recommendation actually had surgery, while in this review, all
patients had surgery. Bilateral cancers, in contrast with
unilateral cancers, more frequently require staged
thoracotomies. As this review included only patients who
actually had resections of their bilateral cancers, it is possible
that some patients who, for whatever reasons, did not undergo
the second thoracotomy would not be included. If the survival
among such omitted patients were poorer than those included
in the analysis, the omission could result in a bias favoring the
group of bilateral cancers, when compared with the group of
unilateral cancers.
The strength of this report includes the fact that it contains
the largest number of analyzed patients with multiple
synchronous lung cancers and it is the first pooled analysis on
this topic. Nevertheless, there are a number of weaknesses.
First, the report contains highly select patients treated at high-
volume centers. Therefore, the favorable survival outcome may
not be generalizable to all patient population. Nonetheless, we
believe that the prognostic factors derived from this dataset
should still be useful for clinical decision making. Second,
variables such as lung function, tumor size, adjuvant therapy,
and comorbidity were not included in our analysis. However,
among a subgroup of 270 patients with available data on
tumor size and adjuvant therapy, we found no substantive
difference in the variables when stratified by the significant
prognostic factors. Third, unlike other variables, histological
similarity is susceptible to nondifferential misclassification,
potentially biasing the effect estimate to the null. Of the six
studies reviewed, only one study [11] specified the pathological
criteria for NSCLC classification and required the availability
of pathological specimens for re-reading. Nevertheless, the null
result is probably more in keeping with usual clinical practice,
when misclassification is probably more frequent than what
observed in this review. Fourth, some authors define
synchronous cancers as those discovered simultaneously.
Nevertheless, the 2-year definition was chosen for this reviewFigure 2. Kaplan–Meier survival curves by the presence of risk factors.
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in accord with the majority of literature based on the fact that
some small lesions, though initially present, may be beyond
radiographic resolution or simply undocumented. Finally, it is
unclear whether other treatment approaches including
stereotactic body radiation or erlotinib [32] will yield a better
result than surgical approach.
Despite these limitations, a number of practical implications
can be derived. First, surgery is a curative treatment option for
patients with synchronous lung cancers in multiple lobes, even
when it is unknown whether the cancers are multiple primary
lung cancers or metastatic disease, and even when the cancers
are bilateral or bear similar histology. Therefore, if such patient
appears to be a good operative candidate, we believe that it is
inappropriate to simply offer palliative chemotherapy without
first seeking a surgical consultation. Second, AJCC staging
appears to largely overstage patients with multiple lung cancers
who underwent curative resections, especially those without
adverse prognostic factors mentioned above. Finally, patients
with N2 (mostly microscopic N2) or N1 have a nearly similar
elevated risk of death. Although long-term survival among
patients with N1 or N2 was observed in our review, these
patients required additional therapies after surgery. Therefore,
the presence of nodal involvement (either N1 or N2),
especially along with other poor prognostic predictors,
indicates an aggressive clinical course and consideration should
be first given to other available curative treatment options.
In summary, among select patients who underwent surgery
for synchronous multiple lung cancers in multiple lobes,
several simple clinical characteristics can serve as survival
predictors. The absence of adverse prognostic factors portends
an excellent long-term prognosis with over 80% estimated
survival rate at 5 years. This exploratory meta-analysis of
published databases may be useful for hypothesis generating
and planning for future prospective studies.
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